Clinical Trial Update: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 trial of Maplirpacept (PF-07901801) in advanced hematologic malignancies, including diffuse large B-cell lymphoma, acute myeloid leukemia, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• Maplirpacept (PF-07901801)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, Multiple Myeloma | Phase 1 | Status: TERMINATED